V. Horn et al., DISPOSITION AND TISSUE DISTRIBUTION OF BORON AFTER INFUSION OF BOROCAPTATE SODIUM IN PATIENTS WITH MALIGNANT BRAIN-TUMORS, International journal of radiation oncology, biology, physics, 41(3), 1998, pp. 631-638
Citations number
29
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: In the frame of the Czech boron neutron capture therapy (BNCT
) project, a clinical Phase I study of borocaptate sodium [Na2B12H11SH
(BSK)] as the boron-10 delivery agent was performed to obtain data on
disposition and tissue distribution of boron after an infusion of thi
s compound, as well as to establish an optimal protocol for BNCT of ma
lignant cerebral tumors. Methods and Materials: The kinetics of boron
disposition after an infusion of borocaptate sodium (25 mg/kg body wt
over the period of 1 h) was studied in a group of 10 patients with ast
rocytoma or glioblastoma of cerebral hemispheres using a modification
of the Soloway-Messer colorimetric method. The boron content of tissue
s (tumor, healthy brain, dura mater, muscle, skin, and cranial bone) r
emoved during the operation performed with latencies varying between 3
and 18 h was investigated by atomic emission spectrometry. Results: C
ompartmental analysis of boron blood concentrations has shown that in
the majority of patients (four males and three females), the concentra
tion decline can be adequately described by a two-compartment pharmaco
kinetic model (i.e., by a biexponential relationship). The calculated
half-lives of the initial (fast) phase of the concentration decline va
ried between 0.85 and 3.65 h, whereas the half-life values for the ter
minal (slow) phase ranged between 22.2 and 111.8 h. However, in the re
maining three patients (all females), the goodness of fit of the boron
concentration data was significantly better when a pharmacokinetic mo
del with three compartments was assumed. In these patients, therefore,
an additional ultrafast phase with a half-life varying between 17 and
37 min was detected in the beginning of the boron blood concentration
decline. On the other hand, in one of these patients, the half-life o
f the terminal phase was found to be 415 h (i.e., more than 17 days).
Such a long persistence in the body is explained by the very high valu
e of the total distribution volume, indicating extensive binding of BS
H in peripheral tissues. Another reason may be enterohepatic recycling
of BSH. Conclusion: Tumor-to-blood ratios higher than 1.5, which are
necessary for an effective outcome of BNCT, can be obtained only if th
e time interval elapsing between the onset of surgery and termination
of BSH infusion is at least 12 h. (C) 1998 Elsevier Science Inc.